Checked November 14, 2026. A selected U.S. tracker for publishers, not an exhaustive statement of every rule. “Proposed,” “pending,” “requested” and “in force” are different statuses. Check the linked primary source before relying on a deadline or changing a campaign. Follow applicable law, platform requirements and the offer brief. See the Telehealth Affiliate Compliance Guide and Compliance Hub.
Current tracked items
Each item separates the verified status from the practical publishing action.
Temporary authorityDecember 31, 2026
DEA telemedicine prescribing flexibilities
The fourth DEA/HHS temporary extension permits qualifying controlled-medication prescribing without a prior in-person evaluation through December 31, 2026, subject to its conditions and applicable federal and state requirements. It is not blanket permission for every remote prescription.
Publisher action: Review “no in-person visit” claims against the advertiser's actual pathway. Do not assume continuation into 2027 or imply that a Medicare extension changes DEA prescribing law.
Pending reviewChecked November 14, 2026
DEA special registration framework
OIRA lists RIN 1117-AB40 as pending at the final-rule stage, received August 25, 2026. A submission for review is not a published effective rule. Proposed requirements should not be presented as the final framework.
Publisher action: Base current claims on an operative authority. Recheck DEA and the Federal Register for final text, effective dates and transition requirements before changing intake promises.
Proposal / existing restrictionsComments closed July 30, 2026
GLP-1s and the 503B bulks list
FDA proposed not including semaglutide, tirzepatide and liraglutide on the 503B bulks list. The extended comment deadline was July 30, 2026. No later final determination was located in this review. Importantly, existing compounding restrictions already apply; a pending proposal does not mean unrestricted 503B bulk compounding is currently allowed.
Publisher action: Verify the pharmacy's actual statutory pathway. Keep 503A patient-specific compounding separate from 503B outsourcing. Do not present added vitamins, a prescription or lower pricing as automatic legal clearance.
Conditional policyAnnounced comment deadline passed
Peptides and the 503A bulks list
The October 30, 2026 Federal Register notice published an HHS draft for comment; the announced November 13 deadline has passed. The policy and appendices describe conditional federal non-enforcement for specified identities and routes of six substances: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. This is not FDA drug approval, a final 503A list addition or a general 503B exemption.
Publisher action: Check current policy, product-specific sourcing, testing, labeling, reporting and state requirements. Do not call the peptides “FDA-approved,” treat the comment deadline as legalization, or extend the policy to every blend, route or research-use-only supplier.
Agenda itemDecember 2026 target
Prescription-advertising risk disclosure
The FDA regulatory agenda for RIN 0910-AJ14 targets a December 2026 proposed rule on direct-to-consumer advertising, including the adequate-provision approach for broadcast risk information. The agenda lists no legal deadline. An agenda target is not an effective rule.
Publisher action: Do not remove existing risk disclosures or assume the scope for podcasts, social media or streaming. Assess the text and effective dates of any subsequently published action.
Pending litigationFTC docket updated November 10, 2026
FTC and states v. Hims & Hers
The FTC docket remains marked pending. Its November 10 amended complaint added five states to the lawsuit over alleged health-data sharing and billing/cancellation practices. Allegations are not adjudicated findings. This tracker does not rely on unverified hearing dates or predictions about dismissal.
Publisher action: Check privacy promises, tracking recipients, actual charge timing and cancellation steps. Do not repeat a competitor's alleged conduct as a proven violation or make unsupported assurances about your own funnel.
Requested label updatesProduct-specific verification
Testosterone labeling
HHS requested testosterone label changes on June 18, 2026, addressing the age-related limitation of use and prostate-related safety wording. FDA's testosterone information page describes the request and the product category. A requested class-wide change is not proof that a particular product's label or indication has changed.
Publisher action: Check the actual current product label. Do not promote TRT as universally appropriate for aging, risk-free or free of monitoring needs. Label changes do not alter DEA prescribing requirements.
Safety communicationNovember 9, 2026
GLP-1 labeling and eye-risk information
FDA required GLP-1 label changes concerning potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause permanent vision loss. This is a safety communication, not a blanket withdrawal of GLP-1 approval.
Publisher action: Ask advertisers to refresh relevant safety language and review existing promotional copy. Do not promise no side effects, minimize material risks or substitute publisher advice for clinical evaluation.
Coverage extensionThrough December 31, 2027
Medicare telehealth coverage
HHS lists many Medicare telehealth flexibilities as extended through December 31, 2027, including specified home/originating-site, provider and communication flexibilities. Some telehealth policies are permanent and others are temporary; coverage details vary.
Publisher action: Keep Medicare payment/coverage rules separate from controlled-substance prescribing and state practice rules. MarketHealth's cash-pay campaign boundary does not authorize insurance-billed affiliate referrals.
Dates and status checks
November 13, 2026 — passedAnnounced HHS peptide comment deadline. It is no longer an upcoming date and does not itself establish a final policy or drug approval.
December 2026 — agenda targetFDA's direct-to-consumer risk-disclosure proposal target, not a guaranteed publication date or compliance deadline.
December 31, 2026 — current DEA extension endsCheck for a published extension, replacement or other applicable authority before describing 2027 remote prescribing.
December 31, 2027 — many Medicare flexibilitiesThis concerns specified coverage/payment policies, not an extension of DEA prescribing authority.
No verified completion dateDEA special registration, the GLP-1 503B proposal, further peptide rulemaking and product-specific testosterone labels need source checks. No court-hearing or advisory-meeting date is asserted here without verification.
Current requirements and enforcement context
A warning letter, complaint, proposal and final rule have different legal significance. The following sources inform review; an enforcement allegation is not a court judgment.
Update log
-
November 14, 2026: Rechecked primary sources; added the November 9 GLP-1 safety communication and November 10 FTC amended complaint. Marked the November 13 peptide deadline as passed. Corrected the distinction between existing compounding restrictions and the 503B proposal, retained the verified July 30 comment extension, verified OIRA review status, replaced secondary-source forecasts with official sources, and separated Medicare coverage from DEA prescribing rules.
The review date records this editorial update. This page does not promise real-time monitoring or a fixed future update schedule. Recheck sources before a launch or material content change.
Primary sources
